BEHANDLUNG VON REFRAKTÄRER MIGRÄNE

European patent · EP3515937 · In force

Register entry

Publication number
EP3515937
Application number
EP17785013
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 22, 2017
Published
Jul 31, 2019
Granted
Dec 17, 2025
Protection ends at the latest
Sep 21, 2037
Next annual fee due
Sep 30, 2027
IPC classes
C07K 16/18 (2006.01)
A61P 25/06 (2006.01)
A61K 39/00 (2006.01)
Priority
US 201662399180 P 23.09.2016
US 201762558557 P 14.09.2017
PCT application
PCT/IB2017/055777 22.09.2017
PCT publication
WO2018/055574 29.03.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 28, 2026

    Change

    Published in Swissreg on 28.10.2026

  2. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  3. Jan 14, 2026

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 14.01.2026

  4. Dec 17, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 17.12.2025

Parties

Holder

Teva Pharmaceuticals International GmbH

Schlüsselstrasse 12, 8645 Rapperswil-Jona

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

BIGAL, Marcelo

Doylestown Pennsylvania 18902, US

AYCARDI, Ernesto

Andover Massachusetts 10810, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.